NASDAQ: CORV TSX: CORV
VANCOUVER, June 18, 2019 /CNW/ - Correvio Pharma Corp.
(NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company
focused on commercializing hospital drugs, today announced the
results of voting at its 2019 Annual General Meeting of
Shareholders held on June 18,
2019.
A total of 31,281,191 common shares were voted in
connection with the meeting, representing approximately 78.39% of
the issued and outstanding common shares of the company.
Shareholders voted as follows:
Election of Directors
By resolution passed by ballot vote, the following seven
nominees proposed by management were elected as directors of
Correvio to hold office until the next annual meeting of
Shareholders or until their successors are elected or
appointed:
|
Nominee
|
Votes For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
|
Richard M.
Glickman
|
10,612,281
|
56.76%
|
8,083,070
|
43.24%
|
|
W. James
O'Shea
|
18,212,631
|
97.42%
|
482,720
|
2.58%
|
|
William L.
Hunter
|
18,223,315
|
97.48%
|
472,036
|
2.52%
|
|
Mark H.
Corrigan
|
18,169,795
|
97.19%
|
525,556
|
2.81%
|
|
Arthur H.
Willms
|
18,222,565
|
97.47%
|
472,786
|
2.53%
|
|
Robert J.
Meyer
|
18,222,560
|
97.47%
|
472,791
|
2.53%
|
|
Vanda de
Cian
|
18,224,350
|
97.48%
|
471,001
|
2.52%
|
Appointment of Auditor
By resolution passed by show of hands, KMPG LLP, Chartered
Professional Accountants, was appointed auditor of the company for
the ensuing year.
About Correvio Pharma Corp.
Correvio Pharma Corp. is a specialty pharmaceutical company
focused on providing innovative, high-quality brands that meet the
needs of acute care physicians and patients. With a commercial
presence and distribution network covering over 60 countries
worldwide, Correvio develops, acquires and commercializes brands
for the in-hospital, acute care market segment. The Company's
portfolio of approved and marketed brands includes:
Xydalba™ (dalbavancin hydrochloride), for the treatment
of acute bacterial skin and skin structure infections (ABSSSI);
Zevtera®/Mabelio® (ceftobiprole medocaril
sodium), a cephalosporin antibiotic for the treatment of community-
and hospital-acquired pneumonia (CAP, HAP); Brinavess®™
(vernakalant IV) for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm; Aggrastat® (tirofiban
hydrochloride) for the reduction of thrombotic cardiovascular
events in patients with acute coronary syndrome, and
Esmocard® and Esmocard Lyo® (esmolol
hydrochloride), a short-acting betablocker used to control rapid
heart rate in a number of cardiovascular indications. Correvio's
pipeline of product candidates includes Trevyent®, a
drug device combination that is designed to deliver treprostinil,
the world's leading treatment for pulmonary arterial
hypertension.
Correvio is traded on the NASDAQ Capital Market (CORV) and the
Toronto Stock Exchange (CORV). For more information, please visit
our web site www.correvio.com.
Correvio® and the Correvio Logo are the proprietary
trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess®™ are trademarks
owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals
International Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed Ltd. and used
under license.
All other trademarks are the property of their respective
owners.
View original
content:http://www.prnewswire.com/news-releases/correvio-announces-voting-results-300870893.html
SOURCE Correvio Pharma Corp